CoChat
Sign Up
Cited by 406Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

Open access
Buzdar, A, Jonat, W, Howell, A, Jones, S E, Blomqvist, C, Vogel, C L, Eiermann, W, Wolter, J M, Azab, M, Webster, A, Plourde, P V·1996·Journal of Clinical Oncology
DOI 10.1200/jco.1996.14.7.2000
Open this paper in CoChat — free account

Abstract

PURPOSE: To compare the efficacy and tolerability of anastrozole (1 and 10 mg once daily), a selective, oral, nonsteroidal aromatase inhibitor, and megestrol acetate (40 mg four times daily), in postmenopausal women who progressed following tamoxifen treatment. PATIENTS AND METHODS: Two randomized, double-blind for anastrozole, open-label for megestrol acetate, parallel-group, multicenter trials were conducted in 764 patients. Because both trials were identical in design, an analysis of the combined results was performed to strengthen interpretation of results from each trial. RESULTS: The median follow-up duration was approximately 6 months. The estimated progression hazards ratios were 0.97 (97.5% confidence interval [CI], 0.75 to 1.24) for anastrozole 1 mg versus megestrol acetate and 0.92 (97.5% CI, 0.71 to 1.19) for anastrozole 10 mg versus megestrol acetate. The overall median time to progression was approximately 21 weeks. Approximately one third of patients in each group benefited from treatment. Twenty-seven patients (10.3%) in the anastrozole 1-mg group, 22 (8.9%) in the anastrozole 10-mg group, and 20 (7.9%) in the megestrol acetate group had a complete or partial response, and 66 (25.1%), 56 (22.6%), and 66 (26.1%) patients, respectively, had stable disease for > or = 24 weeks. For all end points, individual trial results were similar to the results of the combined analysis. Anastrozole and megestrol acetate were well tolerated. Gastrointestinal disturbance was more common among patients in the anastrozole groups than the megestrol acetate group; the difference between the anastrozole 10 mg and megestrol acetate groups was significant (P = .005). Significantly fewer patients in the anastrozole 1-mg (P < .0001) and 10-mg (P < .002) groups had weight gain than in the megestrol acetate group. More than 30% of megestrol acetate-treated patients had weight gain > or = 5%, and 10% of patients had weight gain > or = 10%. Patients who received megestrol acetate continued to gain weight over time. CONCLUSION: Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment. Moreover, anastrozole therapy avoids the weight gain associated with megestrol acetate treatment.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.1996.14.7.2000

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 24 references

Cited by

Sorted by citations

Items 201–300 of 406

Related

See all

Metadata

Authors
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., & Plourde, P. V.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
1996-07
Volume
14
Issue
7
Pages
2000-2011
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.1996.14.7.2000
OpenAlex
W1909697168
Cited by
406
References
24
Citations by year
2025: 2 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 8 · 2018: 2 · 2017: 5 · 2016: 11 · 2015: 7 · 2014: 4 · 2013: 18 · 2012: 10
FWCI
12.96
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
anastrozole, megestrol acetate, aromatase inhibitors, advanced breast cancer, postmenopausal women, progression-free survival, time to progression, complete response, stable disease, gastrointestinal adverse effects, weight gain, drug tolerability, dose comparison, combination chemotherapy, combined radiotherapy, combination endocrine therapy
MeSH terms
Anastrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Double-Blind Method, Female, Humans, Megestrol, Middle Aged, Nitriles, Prognosis, Tamoxifen, Triazoles, Survival Rate, Postmenopause, Disease Progression, Antineoplastic Agents, Hormonal, Megestrol Acetate, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review